Secondary hemochromotosis adJustment in patients with transfusion-dependent Anemia by early administration of low dose deferasirox

Gachon University Gil Medical Center0 个研究点目标入组 103 人开始时间: 待定最近更新: 2019年4月23日

适应症

试验速览

暂无简介。

•Red blood cell transfusion-dependent anemia with low accumulation of iron
•- 50ng/ mL <serum ferritin=500ng/mL
•- Accumulated red blood cell transfusions=10 units
•- Red blood cell transfusion-dependent anemia (receiving more than 2 units of red blood cell transfusion within four months)
•- The causes of anemia include one of the followings:
•Aplastic anemia
•(idiopathic cytopenia of undetermined significance)
•(clonal cytopenia of undetermined significance)
•Idiopathic myelofibrosis
•- Blood disorders requiring long-term red blood cell transfusions
•- Aged 18 years and over
•- Obtaining the informed consent with signature and dates
•- Healthy liver and kidneys (AST, ALT, bilirubin, and creatinine levels below the normal upper limit by 2.5 times).
•- Those who did not achieve CR after the primary induction chemotherapy for the newly diagnosed, therapy naïve AML (if re-induction therapy is performed according to the preliminary plan for primary induction chemotherapy, it is considered that the first-line therapy is performed only.)

•Iron-deficiency anemia (serum ferritin<50ng/mL)
•Acute leukemia
•Medication or treatment-induced anemia
•Myelodysplastic syndrome
•IPSS intermediate-2 or high
•Platelet count <50x109/L
•Progressive malignant tumor
•Patients to receive stem cell transplantation within six months
•Active infections
•Patients difficult to comply with treatment due to psychiatric or cognitive problems
•Hypersensitive to the medicine’s main ingredients or other components
•Creatinine clearance <60mL/min or serum creatinine level doubled from the normal upper limit based on age
•History of treatment with deferasirox
•Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
•pregnancy women

发起方